We are live on ! Find out more
PHP

Parkman Healthcare Partners Portfolio holdings

AUM $970M
1-Year Est. Return 79.46%
This Fund
S&P 500
This Quarter Est. Return
+55.49%
1 Year Est. Return
+79.46%
3 Year Est. Return
+312.89%
5 Year Est. Return
+648.59%
10 Year Est. Return
–
AUM
$355M
AUM Growth
+$139M
Cap. Flow
+$59.2M
Cap. Flow %
16.67%
Top 10 Hldgs %
32.72%
Holding
89
New
23
Increased
24
Reduced
19
Closed
10

Top Buys

Rank Stock Value
1
HUM icon
Humana
HUM
+$11.2M
2
EW icon
Edwards Lifesciences
EW
+$8.53M
3
DHR icon
Danaher
DHR
+$8.09M
4
ABBV icon
AbbVie
ABBV
+$6.6M
5
CTLT
CATALENT, INC.
CTLT
+$6.45M

Top Sells

Rank Stock Value
1
MRK icon
Merck
MRK
+$7.1M
2
VRTX icon
Vertex Pharmaceuticals
VRTX
+$6.19M
3
MNTA
Momenta Pharmaceuticals, Inc.
MNTA
+$4.77M
4
ISRG icon
Intuitive Surgical
ISRG
+$4.49M
5
SDGR icon
Schrodinger
SDGR
+$3.79M

Sector Composition

Rank Sector Weight
1 Healthcare 89.79%
2 Technology 0.89%
3 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VRTX icon
26
Vertex Pharmaceuticals
VRTX
$133B
$5.81M 1.64%
20,000
-22,842
-53% -$6.19M
MDGL icon
27
Madrigal Pharmaceuticals
MDGL
$12.4B
$5.66M 1.6%
50,000
+20,000
+67% +$1.97M
XLRN
28
DELISTED
Acceleron Pharma
XLRN
$5.48M 1.54%
57,500
+20,000
+53% +$1.93M
ALNY icon
29
Alnylam Pharmaceuticals
ALNY
$29.9B
$5.31M 1.5%
35,863
-500
-1% -$67.4K
ITMR
30
DELISTED
Itamar Medical Ltd. American Depository Shares
ITMR
$5.22M 1.47%
280,650
+15,000
+6% +$236K
SILK
31
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
$5.03M 1.42%
120,000
-15,000
-11% -$576K
MTEM
32
DELISTED
Molecular Templates, Inc.
MTEM
$4.73M 1.33%
22,858
– –
BCRX icon
33
BioCryst Pharmaceuticals
BCRX
$2.71B
$4.29M 1.21%
900,608
-95,000
-10% -$379K
RCUS icon
34
Arcus Biosciences
RCUS
$3.69B
$3.96M 1.12%
+160,000
New +$4.32M
KDMN
35
DELISTED
Kadmon Holdings, Inc.
KDMN
$3.71M 1.05%
+725,000
New +$3.25M
KOD icon
36
Kodiak Sciences
KOD
$2.72B
$3.53M 0.99%
65,218
– –
PODD icon
37
Insulet
PODD
$10.1B
$3.4M 0.96%
+17,500
New +$3.35M
NVAX icon
38
Novavax
NVAX
$1.31B
$3.33M 0.94%
+40,000
New +$1.53M
TECX
39
Tectonic Therapeutic
TECX
$721M
$3.33M 0.94%
15,883
-8,750
-36% -$1.8M
AXSM icon
40
Axsome Therapeutics
AXSM
$11.3B
$3.29M 0.93%
+40,000
New +$3.08M
NUAN
41
DELISTED
Nuance Communications, Inc.
NUAN
$3.17M 0.89%
125,056
-25,000
-17% -$522K
IMVT icon
42
Immunovant
IMVT
$8.8B
$3.05M 0.86%
125,125
+85,000
+212% +$1.82M
STXS icon
43
Stereotaxis
STXS
$138M
$2.98M 0.84%
668,693
+15,000
+2% +$60.7K
KALA icon
44
KALA BIO
KALA
$17M
$2.89M 0.81%
110
+20
+22% +$567K
ACRS icon
45
Aclaris Therapeutics
ACRS
$860M
$2.75M 0.77%
1,697,357
+160,000
+10% +$214K
HAE icon
46
Haemonetics
HAE
$4.16B
$2.7M 0.76%
30,147
+15,000
+99% +$1.52M
SPNE
47
DELISTED
SeaSpine Holdings Corporation Common Stock
SPNE
$2.57M 0.72%
245,785
– –
INFU icon
48
InfuSystem Holdings
INFU
$244M
$2.49M 0.7%
215,483
+45,000
+26% +$517K
BBIO icon
49
BridgeBio Pharma
BBIO
$16.4B
$2.45M 0.69%
75,215
– –
TRIL
50
DELISTED
Trillium Therapeutics Inc.
TRIL
$2.43M 0.68%
300,000
-125,000
-29% -$773K
1
2
3 4

Similar funds

LOIM
Liberty One Investment Management Libertyville, Illinois $970M AUM 12.15% 1-Year Est. Return
MGCM
Mane Global Capital Management New York $971M AUM 58.5% 1-Year Est. Return
JWM
Jackson Wealth Management Lake Mary, Florida $972M AUM 22.58% 1-Year Est. Return
WAM
WNY Asset Management Williamsville, New York $967M AUM
GHC
Graham Holdings Company Arlington, Virginia $967M AUM 15.12% 1-Year Est. Return
SAM
Stansberry Asset Management Westlake, Texas $973M AUM 21.39% 1-Year Est. Return
TCCM
Two Creeks Capital Management New York $974M AUM 2.54% 1-Year Est. Return
UIC
Uniplan Investment Counsel Milwaukee, Wisconsin $974M AUM 21.37% 1-Year Est. Return

Parkman Healthcare Partners's Q2 2020 Portfolio in Review

As of Q2 2020, Parkman Healthcare Partners held 89 positions worth $355M, up 64% from $216M the previous quarter. Its ten largest holdings account for 33% of the portfolio.

Parkman Healthcare Partners deployed $59.2M of net new capital in Q2 2020, opening 23 new positions and adding to 24 existing holdings. Its largest new stake was Humana: 30,000 shares worth $11.6M.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, down from 93% a quarter earlier, followed by Technology and Industrials.

On the sell side, the largest reduction was Merck, an estimated $7.1M trimmed.

  • Parkman Healthcare Partners's largest Q2 2020 buy was Humana: 30,000 shares worth $11.6M.
  • Parkman Healthcare Partners added most to GenMark Diagnostics, Inc in Q2 2020, an estimated $6.1M increase.
  • Parkman Healthcare Partners's biggest Q2 2020 reduction was Merck, cutting an estimated $7.1M.
  • Parkman Healthcare Partners fully exited Momenta Pharmaceuticals, Inc. in Q2 2020, selling an estimated $4.77M.
  • Parkman Healthcare Partners's ten largest holdings make up 33% of its $355M portfolio in Q2 2020.
  • Parkman Healthcare Partners opened 23 new positions and closed 10 in Q2 2020.
  • Parkman Healthcare Partners's portfolio value rose 64% quarter-over-quarter to $355M.

Based on Parkman Healthcare Partners's 13F filing for Q2 2020, filed 13 Aug 2020.